CV Therapeutics Feels the Pain
CV Therapeutics' (CVTX) main drug, Ranexa, can only be used as a last-ditch treatment for coronary problems because of concerns that it might cause irregular heartbeats. So when the drug-maker on March 6 announced mixed results from a trial designed to evaluate Ranexa's safety and efficacy, investors sold the stock the next day.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.
- Tesla Unveils ‘World’s Fastest Production Car’ and Electric Big Rig
- Norway Idea to Exit Oil Stocks Is ‘Shot Heard Around the World’
- Getting a Dog May Save Your Life, Especially If You’re Single
- The Questionable Math Behind Manafort’s Extravagant Home Renovations
- World’s Biggest Wealth Fund Wants Out of Oil and Gas